{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:38:54Z","timestamp":1792143534407,"version":"4.4.0"},"reference-count":18,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Histiocytic sarcoma (HS) is a rare hematologic malignancy that has historically been treated with lymphoma-based regimens with a median survival of 6 months. We describe a case of a 51-year-old woman who presented with acute back pain and cord compression. She was diagnosed with HS with diffuse skeletal lesions and high expression of programmed death ligand 1 (PD-L1). She was subsequently treated with chemotherapy plus off-label use of pembrolizumab followed by allogeneic stem cell transplantation. Ultimately, the patient died in the setting of progression of disease 17 months after her stem cell transplantation and 26 months after her diagnosis. This article also presents a literature review of cases of HS treated with programmed death ligand inhibition.<\/jats:p>","DOI":"10.36401\/jipo-23-11","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T14:11:55Z","timestamp":1696515115000},"page":"198-202","source":"Crossref","is-referenced-by-count":11,"title":["Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review"],"prefix":"10.36401","volume":"6","author":[{"given":"Daniel","family":"Huff","sequence":"first","affiliation":[{"name":"1 Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Fortin Ensign","sequence":"additional","affiliation":[{"name":"2 Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S.","family":"Ryan","sequence":"additional","affiliation":[{"name":"3 Department of Pathology, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[{"name":"2 Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"2 Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"2023120211584940200_i2590-017X-6-4-198-b01","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10428194.2018.1492128","article-title":"Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma","volume":"60","author":"Kommalapati","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2023120211584940200_i2590-017X-6-4-198-b02","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ajh.22243","article-title":"Histiocytic sarcoma of the thyroid","volume":"87","author":"Munoz","year":"2012","journal-title":"Am J Hematol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b03","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14694\/EdBook_AM.2013.33.127","article-title":"Molecular profiling and the reclassification of cancer: divide and conquer","author":"Munoz","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2023120211584940200_i2590-017X-6-4-198-b04","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2012.160","article-title":"Targeted therapy in rare cancers\u2014adopting the orphans","volume":"9","author":"Munoz","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b05","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-021-03241-4","article-title":"Safety and efficacy of durvalumab with R-CHOP or R(2)-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial","volume":"115","author":"Nowakowski","year":"2022","journal-title":"Int J Hematol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b06","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b07","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"2023120211584940200_i2590-017X-6-4-198-b08","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023120211584940200_i2590-017X-6-4-198-b09","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"2023120211584940200_i2590-017X-6-4-198-b10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejh.13303","article-title":"Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature","volume":"103","author":"Branco","year":"2019","journal-title":"Eur J Haematol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3892\/mco.2022.2569","article-title":"Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report","volume":"17","author":"Imataki","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"2023120211584940200_i2590-017X-6-4-198-b13","doi-asserted-by":"crossref","first-page":"e27491","DOI":"10.1002\/pbc.27491","article-title":"Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma","volume":"66","author":"Bose","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2023120211584940200_i2590-017X-6-4-198-b14","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","article-title":"Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma","volume":"103","author":"Voruz","year":"2018","journal-title":"Haematologica"},{"key":"2023120211584940200_i2590-017X-6-4-198-b15","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.3324\/haematol.2017.186932","article-title":"Comment on \u201cMEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma","volume":"103","author":"Voruz","year":"2018","journal-title":"Haematologica"},{"key":"2023120211584940200_i2590-017X-6-4-198-b16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.mayocp.2022.05.012","article-title":"Malignant histiocytosis with PD-L1 expression: dramatic response to nivolumab","volume":"97","author":"Campedel","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2023120211584940200_i2590-017X-6-4-198-b17","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/cancers14225489","article-title":"Triple combination of immune checkpoint inhibitors and BRAF\/MEK inhibitors in BRAFV600 melanoma: current status and future perspectives","volume":"14","author":"Welti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023120211584940200_i2590-017X-6-4-198-b18","doi-asserted-by":"crossref","first-page":"693655","DOI":"10.3389\/fonc.2021.693655","article-title":"Triple combination therapy with PD-1\/PD-L1, BRAF, and MEK inhibitor for stage III-IV melanoma: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/198\/3296256\/i2590-017x-6-4-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/198\/3296256\/i2590-017x-6-4-198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:19Z","timestamp":1765475299000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/4\/article-p198.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,2]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-11","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}